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Objective: Obesity is a risk factor for Rheumatoid Arthritis (RA) being associated to low
grade inflammation. This study aimed to determine whether PEDF and Chemerin are
biomarkers of inflammation related to fat accumulation in RA and to investigate whether
weight loss associates with clinical disease improvement through the modification of
fat-related biomarkers in overweight/obese RA with low-moderate disease.
Participants and Methods: Two-hundred and thirty RA patients were enrolled,
of whom 176 at disease onset treated according to a treat-to-target strategy (T2T)
and 54 overweight/obese RA in stable therapy and low-moderate disease activity.
Gene expression of adipokines, interleukin-6 and their receptors were examined in
adipose tissue from obese RA. Obese RA with low-moderate disease activity underwent
low-calories diet aiming to Body Mass Index (BMI) reduction >5%, maintaining RA
therapy unchanged. Chemerin, PEDF and Interleukin-6 plasma values were assessed
by ELISA and disease activity was evaluated.
Results: At RA onset, PEDF and Chemerin plasma values correlated with BMI
(p< 0.001) but only Chemerin plasma values correlated with disease activity (p< 0.001).
After adopting a T2T strategy, Chemerin arose as an independent factor associated with
remission in early RA [OR(95%CIs):0.49(0.25–0.97)]. Moreover, after low-calories diet,
RA with low-moderate disease activity reaching BMI reduction≥5% (62.6%) at 6 months
had significant decrease of PEDF (p < 0.05) and Chemerin (p < 0.05) plasma values, in
parallel with the improvement in disease activity.
Conclusions: PEDF and Chemerin arose as biomarkers of obesity and metaflammation
respectively, providing a link between chronic inflammation and excess of body weight in
RA. Therefore, BMI reduction of at least 5% in obese RA allowed better disease control
without modifying RA treatment.
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INTRODUCTION
Obesity is a risk factor for autoimmune diseases as Rheumatoid
Arthritis (RA) (1–3) since adipose tissue releases adipokines able
to create a low grade inflammatory environment (4–8). However,
the link between obesity and RA is not fully clarified since there
are no parameters available at the moment to understand the
inflammation related to fat accumulation and the behavior of
fat-inflammation under weight loss.
Among adipokines, pigment epithelium derived factor
(PEDF) is one of the most abundant proteins secreted during
adipocytes maturation directly linked to central obesity (9–12).
Recently, Chemerin has emerged as a key adipokine involved
in immune response. Overweight and obese healthy subjects
show higher Chemerin values than normal weight, whose plasma
values decrease after diet (13, 14). Despite Chemerin was found in
inflamed tissues and biological fluids of RA, promoting synovial
fibroblasts hyperplasia (15–17), it is not completely known
whether Chemerin is associated with systemic inflammation or
with adipose tissue activation in RA.
To date, there are only few data regarding the influence of
body fat on RA disease activity suggesting that obesity associates
with disease outcomes (18, 19). Therefore, the aims of our study
were: (i) to dissect whether PEDF and Chemerin are biomarkers
of obesity and fat-related inflammation (metaflammation) in
RA, influencing disease activity at RA onset. Moreover, since
overweight/obesity status influences the chance of good clinical
outcome achievement in RA, (ii) to evaluate whether in obese RA
patients with low-moderate disease activity, weight loss, mirrored
by fat-related biomarkers, without RA treatment change might




To verify the value and role of biomarkers in deciphering
the metaflammation and inflammation course, 176 consecutive
early-RA (ERA) patients, fulfilling the 2010 American College of
Rheumatology criteria for RA (20), were studied at disease onset.
Subjects with symptoms duration <3 months were defined as
“very early RA” (VERA) (21). All ERAwere naïve to conventional
Disease-Modifying Anti-Rheumatic Drugs (cDMARDs) and/or
biological (bDMARDs) and were followed according to the
“treat-to-target strategy” (T2T) (22). For each RA patient, the
ACR/European League Against Rheumatism core data set and
disease activity scores (DAS/SDAI) were recorded (23).
BMI at study entry and during follow-up was recorded for
each patient (24). A comparison of sex and age matched healthy
group (n= 30) was enrolled.
The study was approved by the local Ethical Committee and
all participants gave their signed informed consent.
Study Population-2
Fifty-four overweight/obese RA patients, with moderate disease
activity (DAS < 3.7) for at least 12 weeks despite cDMARDs
and/or bDMARDs treatment were enrolled. Each patient
underwent a dietary intervention (1,000–1,200 kcal/day) (25)
for at least 6 months under nutritionist/psychologist supervision
aiming to a BMI reduction >5% within 6 months without RA
therapy changes (26, 27). Since in any trial of diet induced weight
loss, a mean of 15% of patients do not succeed in obtaining the
5% BMI reduction, we decided to use the unsuccessful subset of
patients as an internal control group (28).
White Adipose Tissue (WAT) Biopsy and Gene
Expression by qPCR in WAT
Twenty-seven of the obese RA patients underwent abdominal
subcutaneous adipose tissue biopsy using an aspiration
technique. Ten age and sex matched obese osteoarthritis (OA)
patients were enrolled as controls.
Total RNA was isolated from adipose tissue in TRIzol R©
(Invitrogen, Carlsbad, CA) according to the manufacturer
protocol. iScriptTM cDNA Synthesis Kit (Bio Rad Laboratories,
Hercules, CA) was used for cDNA preparation. FastStart
Universal Probe Master (Roche Diagnostics, Germany) was used
for qPCR. Primers for human RARRES2 (Chemerin), CMKLR1
(Chemerin receptor23), SERPINF1 (PEDF), IL6, IL6-R, and
GAPDH, as endogenous control, were used (Roche Diagnostics,
Germany). The relative expression fold change of each target
gene was calculated using the comparative CT method with
2∧ − 11CT equation.
Chemerin, PEDF, sIL-6R, and IL-6 Plasma Values
Assessment
For each enrolled RA patient, peripheral blood samples were
collected, immediately processed and stored at −80◦C until
analysis. IL-6, sIL-6R, PEDF and Chemerin plasma values were
measured by ELISA (R&D Systems, UK). The sensitivity of the
test was 0.7 pg/ml for IL-6, 6.5 pg/ml for sIL-6R, 0.045 ng/ml for
PEDF and 4.13 pg/ml for Chemerin.
Statistical Analysis
Statistical analysis was performed using SPSS (SPSS version 20.0,
Chicago, IL, USA) and Graph-Pad Prism statistical software
(San Diego, CA, USA). Categorical and quantitative variables
were recorded as frequencies, percentages, mean ± Standard
Deviation (SD). The non-parametric Mann-Whitney U-test and
the χ2 test were used, as appropriate. The Spearman rank
correlation was used to evaluate the relationship between fat-
related parameters and inflammatory and clinical parameters
and the Wilcoxon test was used to compare the clinical
parameters and the soluble biomarkers during follow-up. A
receiver operating characteristic (ROC) analysis of the adipokines
related to BMI was performed.
Sample size for Study population-2 was calculated by
G∗Power 3.1 software (29) using as reference the successful
rate of outcome achievement (BMI reduction > 5%) in the
general population (27), obtaining a minimum sample size of 41
individuals with a study power of 82.2% and α = 0.04.
A multivariate logistic regression model, in which “DAS or
SDAI remission at 6 or 12 month follow-up visit” were the
dependent variables to be explained, was performed and results
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were expressed as the odds ratio (OR) and 95% confidence
interval (95%CI). Statistical significance was defined as p < 0.05.
RESULTS
Overweight and Obesity Status, Mirrored
by Adipokines Milieu, Is Related to Disease
Activity of RA Patients at Onset
To dissect the contribution of fat mass on clinical phenotype
at RA onset, 176 ERA patients were enrolled as investigational
cohort (Study population-1). Baseline demographic and clinical
characteristics are shown in Table 1. Overweight and obese ERA
patients showed higher disease activity than normal weight ones
(Table 1) (Figure 1A) (Supplemental Table 1).
Moreover, to investigate whether specific molecules related
to adipose tissue excess are associated with the inflammatory
burden of RA, PEDF, and Chemerin plasma values were assessed
in RA patients at disease onset compared to healthy subjects
stratified by BMI category [30 healthy individuals, among whom
70% female, with a mean age of 50.0 years (SD = 9.6) and 12
(40.0%) overweight or obese].
PEDF and Chemerin plasma values were similar in ERA
patients at diagnosis (PEDF: 13.1 ± 3.9µg/ml, Chemerin: 108.6
± 52.2 ng/ml) and controls (PEDF: 13.7 ± 2.4µg/ml; p = ns;
Chemerin: 95.2 ± 34.1 ng/ml; p = ns), while IL-6 plasma values
were significantly higher in ERA patients than in controls (20.3
± 34.5 pg/ml vs. 1.6 ± 3.8 pg/ml; p < 0.001). No significant
difference was found between the sIL-6R plasma values at study
entry comparing RA patients and controls (p = 0.34). Moreover,
in ERA cohort, PEDF and Chemerin values directly correlated
with age at the time of diagnosis (Supplemental Table 1).
However, higher plasma values of PEDF and Chemerin were
observed in overweight/obese individuals than in normal weight
ones (Figures 1B,C) and this difference remained significant only
for Chemerin after age and sex adjustment (p = 0.01) (Table 1).
Moreover, overweight/obese ERA patients showed higher IL-6
plasma values (26.8 ± 43.1 pg/ml) compared to normal weight
(13.8 ± 21.3 pg/ml; p = 0.01) at baseline directly correlating
with Chemerin plasma values (R= 0.25; p= 0.003). Considering
sIL-6R in ERA cohort, overweight/obese ERA patients did not
differ from normal weight ones at baseline (p = 0.85) with no
significant correlation with Chemerin plasma values (R=−0.14;
p= 0.36) at disease onset.
TABLE 1 | Demographic, immunological and clinical characteristics of Study populations 1 and 2.
Study population-1 Study population-2
All BMI ≥ 25 Kg/m2 BMI < 25 Kg/m2 p-value p-value*
N 176 89 87 54
Age, years 56 ± 15 58 ± 13 53 ± 16 0.02 57 ± 12
Symptom#/Disease##’s duration, months#/years## 5.6 ± 3.5 5.2 ± 3.2 6.1 ± 3.6 0.09 5.9 ± 3.6
Sex, n. female (%) 135 (76.7) 63 (70.8) 72 (82.8) 0.06 46 (85.2)
BMI, Kg/m2 25.3 ± 4.8 – – – 35.2 ± 4.1
Overweight, n(%) 63 (35.8) – – – 4 (7.4)
Obesity, n(%) 26 (14.8) – – – 50 (92.6)
ACPA positivity, n(%) 104 (59.1) 54 (60.7) 50 (57.5) 0.67 46 (48.1)
RF-IgM positivity, n(%) 84 (47.7) 46 (51.7) 39 (44.8) 0.36 22 (40.7)
RF-IgA positivity, n(%) 51 (29.0) 30 (33.7) 21 (24.1) 0.16 14 (25.9)
ESR, mm/1∧hour 41.4 ± 28.7 44.3 ± 27.7 38.5 ± 29.5 0.07 0.49 35.3 ± 22.9
CRP, mg/l 21.3 ± 31.5 25.7 ± 36.4 16.8 ± 25.0 0.02 0.24 9.5 ± 10.8
IL6, pg/ml 21.7 ± 42.6 26.7 ± 43.1 13.8 ± 21.3 0.01 0.09 10.7 ± 20.2
sIL6-R, ng/ml 56.2 ± 19.3 57.8 ± 22.1 54.8 ± 16.8 0.85 0.83 47.3 ± 23.9
TJC 11.3 ± 6.9 12.28 ± 7.29 10.32 ± 6.41 0.06 0.04 5.6 ± 4.2
SJC 8.4 ± 5.8 8.80 ± 5.51 7.91 ± 6.04 0.13 0.37 3.7 ± 3.2
HAQ 1.1 ± 0.8 1.25 ± 0.75 1.01 ± 0.76 0.02 0.08 1.1 ± 0.6
DAS 3.4 ± 0.9 3.5 ± 1.0 3.3 ± 0.9 0.02 0.09 2.8 ± 0.8
SDAI 29.3 ± 14.3 30.8 ± 14.3 27.8 ± 14.3 0.09 0.36 15.8 ± 9.3
bDMARDs, n(%) – – – – – 25 (46.3)
Chemerin, ng/ml 108.6 ± 52.2 120.7 ± 57.1 96.2 ± 43.6 0.002 0.01 53.7 ± 19.0
PEDF, µg/ml 13.1 ± 3.9 13.7 ± 3.9 12.5 ± 3.8 0.02 0.18 16.5 ± 3.2
Values are mean ± standard deviation unless otherwise indicated. ERA, early rheumatoid arthritis; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein;
DAS, disease activity score; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; TJC, tender joint count; SJC, swollen joint count; HAQ, Health Assessment Questionnaire;
SDAI, simplified disease activity index; bDMARDs, biological Disease Modifying Anti-Reumatic Drugs; PEDF, pigment epithelium-derived factor.
# for Study population-1 and ## for Study population-2.
P-value: Mann-Withney test overweight/obese patients vs. normal weight patients.
P-value*: Mann-Withney test overweight/obese patients vs. normal weight patients corrected for age and sex.
P-value < 0.05 were considered statistically significant.
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FIGURE 1 | Body mass index, PEDF and Chemerin plasma values are reciprocally related and associated to disease activity in ERA patients at disease onset.
(A) Correlation between disease activity and BMI in ERA patients at baseline. (B,C) Plasma adipokines (PEDF and Chemerin) values in ERA patients at diagnosis and
controls based on the BMI category. (D) Correlation between disease activity and PEDF and Chemerin plasma values in ERA patients at baseline.
These data were confirmed by the positive correlation
between PEDF, Chemerin and IL-6 plasma values and BMI
(Supplemental Figure 1) (Supplemental Table 1). Optimal
Chemerin cut-off value associated with BMI ≥ 25 Kg/m2 was
95.7 ng/ml with sensitivity and specificity of 60.0 and 60.9%,
respectively. Optimal PEDF cut-off value associated with a BMI
≥ 25 Kg/m2 was 13.3 ug/ml with a sensitivity and specificity of
50.3 and 63.2%, respectively (Supplemental Figure 2).
Chemerin but Not PEDF Plasma Values Are
Independently Associated With Baseline
Disease Activity in ERA Patients
In ERA patients (Study population-1), Chemerin but not
PEDF plasma values positively correlated with disease activity
scores (DAS: R = 0.33; p < 0.001; SDAI: R = 0.30;
p < 0.001) and disability index (HAQ: R = 0.21; p = 0.01)
(Supplemental Table 1 and Figure 1D).
In particular, ERA patients with Chemerin plasma values
≥ 95.7 ng/ml had more likely a moderate-high disease activity
(46.6%) compared to RA patients with Chemerin plasma
values < 95.7 ng/ml (27.6%; p = 0.01). On the contrary, no
significant association was observed between PEDF plasma
values and disease activity at diagnosis.
Chemerin but Not PEDF Plasma Levels
Values Are Independently Associated With
Clinical Outcome in ERA Patients Treated
According to Treat to Target Strategy
In the whole ERA cohort (Study population-1), DAS remission
was achieved by 40.7 and 50.4% after 6 and 12 months follow-up,
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respectively, and SDAI remission status by 29.1% at 6 and
35.7% at 12 months follow-up, respectively. Overweight/obesity
per se was not influencing remission achievement (Table 2).
However, a higher and faster remission rate was reached
by RA patients having Chemerin plasma levels <95.7 ng/ml
at baseline (Figures 2A,B), despite similar bDMARDs usage
(Table 2), in addition to being VERA or having a high disease
activity at the time of diagnosis (Table 2). On the contrary,
high PEDF plasma levels values didn’t influence treatment
response (Table 2). The logistic regression analysis confirmed the
independent association between therapy response at 12 months
and Chemerin plasma values at baseline [OR(95%CIs):0.49(0.25–
0.97)], together with being VERA [OR(95%CIs):2.05(1.00–4.23)],
suggesting that low Chemerin plasma values is a predictor of
remission (Table 2). This association was observed also using a
stricter remission parameter as SDAI (28.6% of SDAI remission
in ERA patients having Chemerin plasma values ≥95.7 ng/ml
vs. 42.4% of SDAI remission in ERA patients having Chemerin
plasma values<95.7 ng/ml; p= 0.10). These findings suggest that
a low Chemerin plasma values is a positive predictor of remission
achievement in RA.
As previously stated, a significant disease activity reduction
at 6 and 12 months was observed in both normal weight and
overweight-obese ERA patients. Similarly, Chemerin plasma
values significantly decreased over time reaching comparable
levels already after 6 months in overweight/obese and normal
weight RA patients, showing a higher rate of Chemerin plasma
values reduction in overweight/obese compared to normal weight
ERA patients (Figure 2C). On the contrary, PEDF plasma values
remained unchanged during the follow-up (data not shown). The
entity of Chemerin plasma values reduction was found tightly
related to the initial BMI (R = 0.26; p = 0.02) and directly
correlated with the DAS value reduction (R = 0.24; p = 0.03)
in ERA patients (Figure 2D). Furthermore, this finding was
confirmed by the direct correlation between Chemerin plasma
values reduction and the delta SDAI (R = 0.28; p = 0.02).
Therefore, in ERA patients changes of Chemerin plasma values
but not of PEDF, throughout the T2T treatment, is associated
with baseline BMI and mirrors the reduction of disease activity
despite stable body weight.
Adipose Tissue of Obese RA Patients
Shows Different Expression of Adipokines,
IL-6 and Their Receptors Based on
Disease Activity
To reveal whether WAT of patients with RA shows different
gene expression profile based on disease itself and/or fat-related
inflammation, we investigated the quantitative expression of
RARRES2, CMKLR1, SERPINF1, IL6, and IL6-R inWAT of obese
RA (BMI: 35.5± 4.1 Kg/m2) and OA (BMI: 34.8± 3.2).
In particular, we found that SERPINF1 was highly expressed
in WAT of RA (2.7 ± 1.6 fold change) than OA patients (1.5
± 1.2 fold change; p = 0.03), mainly in RA with moderate
disease activity (MDA) (Figure 3A). No differences were seen
for RARRES2 and IL6 expression in WAT between the whole
obese RA and OA cohorts. However, stratifying patients based
on the disease activity, WAT from MDA RA showed higher
IL6 expression compared to RA patients with low disease
activity (LDA) (Figure 3A). Increased expression of CMKLR1
was observed in WAT of obese RA (7.2 ± 12.1 fold change)
compared to OA (2.3 ± 3.7 fold change; p = 0.02), particularly
in MDA RA (7.4 ± 12.1; p = 0.04) (Figure 3B). Finally, no
correlation was found between adipokines and their receptors
expression inWAT and Chemerin, PEDF or IL6 plasma values or
disease activity (i.e., DAS) in obese RA patients (data not shown).
TABLE 2 | Logistic regression analysis showing factors independently associated with DAS-remission (DAS < 1.6) at 6 and 12 months of follow-up in a cohort of ERA

















Age, years 0.97 (0.935–0.997) 0.97 (0.95–0.99) 0.98 (0.96–1.01) 0.99 (0.96–1.01)
Sex (female) 0.65 (0.30–1.41) – 0.55 (0.26–1.20) –
VERA 2.22 (1.08–4.55) 2.75 (1.26–5.98) 2.10 (1.03–4.28) 2.05 (1.00–4.23)
Current Smokers, n. (%) 0.72 (0.33–1.58) – 0.68 (0.32–1.44) –
BMI ≥ 25 Kg/m2 0.65 (0.34–1.24) – 0.75 (0.38–1.49) –
AB positivity, n. (%) 1.23 (0.58–2.71) – 1.27 (0.60–2.66) –
DAS > 3.7 (active disease at baseline) 0.33 (0.15–0.76) 0.37 (0.16–0.88) 0.65 (0.32–1.35) –
bDMARDs at 3 months FU 0.51 (0.13–2.05) – 1.78 (0.49–6.42) –
bDMARDs at 6 months FU – 1.14 (0.39–3.35) –
Chemerin ≥ 95.7 ng/ml 0.47 (0.23–0.95) 0.66 (0.31–1.43) 0.48 (0.24–0.94) 0.49 (0.25–0.97)
PEDF ≥ 13.3µg/ml 0.84 (0.42–1.67) – 1.03 (0.53–2.02) –
VERA, Very Early Rheumatoid Arthritis patients; BMI, Body Mass Index; AB, Autoantibodies; DAS, Disease Activity Score; bDMARDs, biological Disease Modifying Anti-Rheumatic
Drugs; FU, follow-up; PEDF, Pigment Epithelium Derived Factor; OR, Odds Ratio; CI, Confidential Interval; FU, Follow-up. *Mann–Whitney U-test or χ2 test. Bold, p-value < 0.05.
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FIGURE 2 | Association between chemerin plasma values and response to therapy over time in ERA patients treated according to a treat-to-target (T2T) strategy.
(A) Association between Chemerin plasma values and percentage of remission (DAS < 1.6) at 3, 6, and 12 months of T2T treatment. (B) Kaplan-Meier survival curve
in ERA patients achieving remission over 1 year stratified for the baseline Chemerin plasma values cut-off point (Log Rank test: χ2:8.72; p = 0.003;
Breaslow-Wilcoxon text: χ2:7.24; p = 0.01). (C) Chemerin plasma values at baseline and during treat to target protocol (at 6 and 12 months) in ERA patients; *p <
0.05 vs. baseline in ERA patients with BMI ≥ 25 Kg/m2, §p < 0.05 vs. baseline in ERA patients with BMI < 25 Kg/m2; #p < 0.05 for difference at different time
points between BMI ≥ 25 Kg/m2 and BMI < 25 Kg/m2. (D) Correlation between changes in Chemerin plasma values, BMI at baseline and disease activity; Delta,
(value at baseline - value at 12 months); Fold change, Delta/(value at baseline).
Weight Loss Induces Chemerin and PEDF
Plasma Values Reduction, Influencing the
Remission Achievement in
Overweight/Obese RA Patients
We enrolled 54 overweight/obese RA patients with low-
moderate disease activity, despite a treat to target strategy
treatment, undergoing low calories diet for at least 6 months
(Study population-2) (Table 1). During the follow-up, the
mean BMI reduction was 2.5 ± 1.8 Kg/m2 (corresponding
to 7.4 ± 5.7% of initial BMI) at 6 months and 3.1 ±
2.4 Kg/m2 (corresponding to 8.9 ± 6.8% of initial BMI)
at 12 months of diet, respectively. However, 7 (13.0%) RA
patients did not show any change in BMI during the follow-
up.
To clarify whether weight loss was directly associated with
adipokines modulation in RA patients, Chemerin and PEDF
plasma values were tested at baseline and after a low-calories
diet (Study population-2). A significant reduction of Chemerin
and PEDF plasma values was observed since the 6TH month
of low-calories diet, in patients achieving ≥5% BMI reduction
(Figures 4A,B). Moreover, a direct correlation between the BMI
fold change (baseline/6 months) and Chemerin plasma values
fold change was found (R = 0.30; p = 0.04) (Figure 4C),
whereas there was no correlation with PEDF plasma values
fold change. Finally, RA patients achieving a decrease of
BMI ≥ 5% at 6 months showed a significant reduction of
sIL-6R plasma values at 12 months follow-up (47.9 ng/ml at
baseline vs. 40.4 ng/ml at 12 months follow-up; Wilcoxon test:
p = 0.04), not observed in RA patients with BMI reduction
<5% during the same follow-up period (p = 0.10). IL-6
plasma values were similar in the two subgroups (data not
shown).
RA patients with low-moderate disease activity (Study
population-2) reducing ≥5% the baseline BMI after 6
months, showed a significant reduction of disease activity
after 6 and 12 months, without any pharmacological change
(Supplemental Figure 3):34 RA patients reaching ≥5% BMI
reduction after 6 months and 19 with ≥10% BMI reduction
after 12 months, obtained higher DAS remission rates than
patients with a less significant BMI reduction. In addition, 39.4%
of RA patients experiencing BMI decrease ≥5% achieved DAS
remission at 6 months follow-up compared to 10.0% of RA
patients achieving BMI decrease <5% (p = 0.02), whereas 55.6%
RA patients experiencing BMI decrease ≥10% achieved DAS
remission at 12 months follow-up compared to 15.0% of RA
patients achieving BMI decrease <10% (p = 0.01). The effect
of weight reduction on disease activity was already seen at 6
months, as confirmed by the positive correlation between the
BMI fold change (baseline/6 months) and delta DAS (R = 0.45;
p= 0.001) as well as delta SDAI (R= 0.49; p < 0.001).
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FIGURE 3 | Chemerin, PEDF, IL6 and their receptors expression in White Adipose Tissue (WAT) of obese RA patients with low-moderate disease activity and in obese
OA. (A) IL6, RARRES2, and SERPINF1 expression and (B) CMKLR1 and IL6-R were determined in abdominal WAT from obese RA (n = 27) and obese OA (n = 10).
Levels of target genes mRNA expression were determined, after normalization with GAPDH values, using the 2−11CT method. Horizontal lines indicate mean values
with SD. RA, Rheumatoid Arthritis; OA, Osteoarthritis; LDA, Low disease activity (1.6 < DAS < 2.4); MDA, Moderate disease activity (2.4 < DAS < 3.7); IL6,
Interleukin 6; RARRES2, retinoic acid receptor responder protein 2; CMKLR1, Chemokine like receptor 1; IL6-R, interleukin-6 receptor.
FIGURE 4 | Effect of weight loss on Chemerin and PEDF plasma values. Mean changes in Chemerin (A) and PEDF (B) plasma values from baseline in
overweight/obese RA patients with a low-moderate disease activity undergoing scheduled dietetic regimen aiming at BMI reduction. RA patients were divided based
on the percentage of reduction of BMI (< or ≥ 5%); *: p ≤ 0.05. (C) Correlation between changes in BMI, plasma values of Chemerin and disease activity; Delta,
(value at baseline - value at 6 months); Fold change, Delta/(value at baseline).
DISCUSSION
Over the last years, understanding the importance of overweight
and obesity during RA disease course, from the disease
onset through its progression and outcome has increased and
improved. To date, adipose tissue arose as a dynamic endocrine
organ that releases bioactive substances secreted by adipocytes
and adipose tissue resident macrophages shared with chronic
inflammatory diseases as RA (30). Most of these molecules
show pro-inflammatory properties accounting for a low-grade
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systemic inflammation. Among them, Chemerin appears to be
a crucial inflammatory mediator in RA, correlating with disease
activity rather than obesity (17, 31) whereas PEDF plays a role in
the promotion of inflammation (9, 12).
Our data show that Chemerin plasma values positively
correlate with BMI and disease activity in RA patients at
diagnosis. Moreover, a low calories Mediterranean diet induces
weight loss in an important percentage of overweight/obese RA
patients, increasing the number of patients achieving disease
remission. In fact, we observed, for the first time, that a significant
percentage of RA patients with low-moderate disease activity
can be led to clinical remission without any treatment change
by loosing at least 5% of baseline BMI which is a commonly
recommended therapeutic target for obese people leading to
profound health benefits (28, 32). In particular, effective dietary
intervention significantly affects direct and indirect adipose
tissue-related inflammatory markers, as Chemerin and sIL-6R
respectively, possibly by positively reducing the recruitment of
adipose tissue macrophages as the underlying features of meta-
inflammation (33, 34). These data underline the importance of
fat-derived inflammatory mediators on disease activity in obese
RA patients.
Since the direct link between high BMI and disease activity at
RA onset is still a matter of debate, we investigated the clinical
features of RA patients at disease onset stratified according
to their BMI category. Interestingly, we found that, at disease
onset, overweight/obese RA patients had higher disease activity
compared to normal weight ones. Moreover, analyzing the
influence of body weight excess in terms of adipose tissue derived
inflammatory markers on the remission rate achievement in
ERA patients treated with the T2T scheme, high Chemerin
plasma values at diagnosis were negatively associated to the
achievement of good disease control after the T2T scheme. The
impact of obesity on clinical outcome was previously investigated
in long standing RA (8) despite the controversial indirect link
between obesity and bone erosiveness (18, 35, 36). Considering
adipose tissue derived adipokines, Ha et al previously found an
indirect correlation between BMI and Chemerin plasma values
evaluated in a limited RA cohort, stating that Chemerin plasma
values could be associated with systemic inflammation rather
than obesity in RA. However, this latter cohort was made of
already treated patients with long standing disease and no data
were reported about Chemerin plasma values at disease onset
(17). It should be considered that, in the general population,
Chemerin plasma values directly correlate not only with the
obesity status, in terms of BMI category, total body fat percentage,
waist circumference and total lipids asset but even with multiple
markers of chronic inflammation (i.e., CRP, SAA, IL-6, and
sTNFRII) suggesting that it may induce extensive inflammatory
processes in various chronic inflammatory disorders (37).
In our ERA cohort, a significant association between
Chemerin and PEDF plasma values and parameters of systemic
inflammation was found at the time of diagnosis, even though
only Chemerin plasma values positively correlated with disease
activity. These data mirror cytokines’ behavior, as IL-6, which is a
crucial player in the inflammatory cascade at the earliest stages
of RA (38), suggesting that Chemerin may play a role in RA,
mainly in patients with high BMI. Interestingly in our study,
higher Chemerin plasma values at disease onset, but not the
overweight-obesity status nor higher PEDF plasma values, was
associated with remission achievement, identifying Chemerin as
a biomarker of metaflammation and as a modifiable risk factor
associated with RA treatment response (16, 39).
In animal models, it is well documented that high-
fat diet induces a low-grade chronic inflammation called
metaflammation (40) leading to the production of pro-
inflammatory cytokines as IL-1, IL-6, and Tumor Necrosis Factor
(41–43), all over-expressed at the early phases of RA (38).
These pro-inflammatory cytokines affect synovial and adipose
tissues causing inflammation that promotes the recruitment and
activation of immune cells within these target tissues and the
amplification of the inflammatory loop in RA (44, 45). Based on
this, we investigated the gene profile of IL-6, Chemerin/ChemR23
and PEDF in abdominal adipose tissue derived from obese RA
patients, finding a higher expression of IL-6, ChemR23, and
PEDF in WAT of obese RA patients with MDA than in obese
OA. These findings suggest that the gene expression profile
of pro-inflammatory mediators in WAT is tightly related to
the inflammatory status mirroring the disease activity phases
in obese RA. Moreover, studies on animal models revealed
that obesity influences the degree of inflammation in another
biological compartment involved in RA pathogenesis, as synovial
tissue, which seems to be affected by high fat diet mainly
at the earliest disease phases in terms of synovial hyperplasia
and inflammatory cells infiltrates with no significant differences
between obese and lean animals after disease establishment (46).
In conclusion, PEDF and Chemerin can be biomarkers
of obesity and metaflammation in RA patients respectively.
In particular, Chemerin seems to be linked to RA disease
activity and treatment response, supporting its dual role in
mirroring inflammation and metabolism and providing a link
between chronic inflammation and obesity. Based on that, a BMI
reduction of at least 5%, mirrored by Chemerin modulation,
allows the achievement of a better disease control without
changing RA treatment.
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